Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015–present)

Alshaima’a M. Qunies, Kyle A. Emmitte

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Group II metabotropic glutamate (mGlu) receptors have emerged as an attractive potential target for the development of novel CNS therapeutics in areas such as Alzheimer’s disease (AD), anxiety, cognitive disorders, depression, and others. Several small molecules that act as negative allosteric modulators (NAMs) on these receptors have demonstrated efficacy and/or target engagement in animal models, and one molecule (decoglurant) has been advanced into clinical trials. Areas covered: This review summarizes patent applications published between January 2015 and November 2020. It is divided into three sections: (1) small molecule nonselective mGlu2/3 NAMs, (2) small molecule selective mGlu2 NAMs, and (3) small molecule selective mGlu3 NAMs. Expert Opinion: Much progress has been made in the discovery of novel small molecule mGlu2 NAMs. Still, chemical diversity remains somewhat limited and room for expansion remains. Progress with mGlu3 NAMs has been more limited; however, some promising molecules have been disclosed. The process of elucidating the precise role of each receptor in the diseases associated with group II receptors has begun. Continued studies in animals with selective NAMs for both receptors will be critical in the coming years to inform researchers on the right compound profile and patient population for clinical development.

Original languageEnglish
JournalExpert Opinion on Therapeutic Patents
DOIs
StateAccepted/In press - 2021

Keywords

  • Alzheimer’s disease
  • anxiety
  • cognition
  • Decoglurant
  • depression
  • metabotropic glutamate receptor subtype 2
  • metabotropic glutamate receptor subtype 3
  • negative allosteric modulator

Fingerprint

Dive into the research topics of 'Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015–present)'. Together they form a unique fingerprint.

Cite this